GlaxoSmithKline (GSK) has submitted a Japanese New Drug Application (JNDA) for its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), daprodustat, representing the first regulatory filing for the renal anemia therapy.
Around 3.5 million patients in Japan have anemia assOriginal Article
